The US initial public offering market entered the fourth quarter of 2026 with mixed signals. Third-quarter proceeds were dominated by one mega-deal, late-September trading erased earlier gains for new issues, and the year-end calendar now hinges on a possible blockbuster listing. According to Renaissance Capital, a fall pickup in activity “stumbled” on concerns about artificial intelligence spending, a 19-year high in bond yields and resumed rate hikes.

Third quarter by the numbers

Renaissance Capital’s third-quarter review counted 30 US listings, a fairly modest total that was lowered by a string of postponements near quarter-end. Proceeds reached $32.8 billion, but most of that came from a single transaction: SK hynix, the Korea-listed memory chip maker, raised $26.5 billion in its US offering. Excluding that deal, proceeds were $6.2 billion.

  • Deal count: 30 listings in the quarter.
  • Total proceeds: $32.8 billion, or $6.2 billion excluding SK hynix.
  • Larger deals: 18 IPOs raised $100 million or more.
  • Themes: biotech and AI infrastructure remained the main themes, while consumer and financial issuers also tested the market.

Renaissance noted a wider variety of businesses coming to market than in prior quarters, a sign that issuer interest was not confined to a single industry.

Aftermarket performance cooled

New issues gave back ground late in the quarter. Renaissance reported that the quarter’s IPOs averaged a flat return, as weak trading in late September erased earlier gains. The Renaissance IPO Index fell 11% amid a selloff in growth stocks and underperformed the S&P 500 for the quarter.

The longer view is more favorable. As of October 1, the Renaissance IPO Index was up 16.4% year to date, compared with a 13.0% gain for the S&P 500. Its international counterpart was up 28.5% year to date, versus 13.8% for the ACWX benchmark.

A record-setting year, with caveats

Earlier in the year the market was running at historic levels. Axios, citing Renaissance Capital, reported in mid-July that US IPO proceeds for 2026 had reached $141.2 billion, just short of the 2021 record of $142.4 billion, with additional large pricings expected that week. The same report put annual US proceeds at $46.3 billion in 2019 and at a low of $7.7 billion in 2022, illustrating how sharply issuance can swing with market conditions.

Because so much of 2026’s total reflects a handful of very large offerings, deal count and proceeds can tell different stories. Investors who follow the IPO market often look at both measures, along with how recent listings trade after pricing.

What is on the calendar

The start of the fourth quarter was quiet. Renaissance’s week-ahead preview for early October listed two small biotech offerings:

  • TRex Bio (TRXB): a planned $125 million deal at $14 to $16 per share, with an autoimmune focus.
  • Retension Pharmaceuticals (RTSN): a planned $40 million deal at $11 to $13 per share, focused on hypertension.

Both companies are clinical-stage, and the terms above were preliminary at the time of the preview. Four lock-up expirations were also scheduled that week; lock-ups end restrictions on insider selling and can add supply to the market.

Anthropic looms over the fourth quarter

The largest question for the rest of the year is the timing of a possible listing by Anthropic. Renaissance said the company is preparing a public filing and is expected to headline the fourth-quarter calendar, and a later update reported that marketing could begin as soon as the week of November 9. Renaissance also said OpenAI is now expected to wait until 2027 to list.

The firm cautioned that upcoming midterm elections and the size of a potential Anthropic offering complicate the year-end timeline. It said deal flow for the remainder of 2026 depends on market stabilization and on recent IPOs holding their returns. Filings were muted near the end of the third quarter as growth stocks pulled back.

How to read IPO data

  • Look past the headline total. One mega-deal can account for most of a quarter’s proceeds, as SK hynix did in the third quarter.
  • Check aftermarket returns. Pricing is one measure of demand; trading afterward shows whether buyers stayed interested.
  • Watch lock-up dates. Expirations can change the supply of shares available to trade.
  • Consider the rate backdrop. Higher yields tend to weigh on growth-oriented issuers, which make up much of the IPO pipeline.

Outlook

The IPO market remains ahead of the broader index for 2026, but momentum slowed as the quarter ended. Whether the fourth quarter delivers a rebound will depend on how growth stocks trade, how recent listings hold up, and whether large issuers move forward with their plans.

This article is for informational purposes only and is not investment advice.

Sources: Renaissance Capital; Axios.